Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 42-year-old woman is evaluated in the clinic prior to a change in her medication regimen. She has a 4-year history of seropositive rheumatoid arthritis. For the past year, she has been managed with sulfasalazine and hydroxychloroquine, but she reports persistent morning stiffness lasting over two hours and increasing pain in her wrists and hands. Examination shows synovitis with effusions in the bilateral wrists, metacarpophalangeal joints, and proximal interphalangeal joints. Radiographs of the hands reveal new periarticular erosions. The physician decides to discontinue sulfasalazine and initiate therapy with methotrexate and infliximab. The patient has no history of cardiovascular or liver disease, and her physical examination is otherwise unremarkable. Which of the following baseline screening tests are strictly required before initiating this new pharmacologic regimen? (Select all that apply)

  1. Interferon-gamma release assayCevap
  2. Hepatitis B surface antigen and core antibodyCevap
  3. C
    Transthoracic echocardiography
  4. D
    Thiopurine methyltransferase enzyme activity
  5. E
    Antinuclear antibody and anti-double-stranded DNA levels

Cevap

The required baseline screening tests before initiating a TNF-alpha inhibitor and methotrexate are an interferon-gamma release assay (or tuberculin skin test) and hepatitis B surface antigen and core antibody testing.
The correct baseline monitoring parameters for a patient starting a tumor necrosis factor (TNF)-alpha inhibitor (infliximab) and methotrexate include an interferon-gamma release assay (or tuberculin skin test) and hepatitis B surface antigen and core antibody testing. TNF-alpha is essential for maintaining granulomas that sequester Mycobacterium tuberculosis. Inhibiting TNF-alpha greatly increases the risk of reactivating latent tuberculosis infection, making baseline screening mandatory. Furthermore, both methotrexate and TNF-alpha inhibitors are potent immunosuppressants associated with a significant risk of hepatitis B reactivation, which can lead to fulminant hepatic failure. Consequently, all patients must have baseline serologic testing for hepatitis B prior to initiating therapy.

Adım Adım Çözüm

1
Identify the proposed high-risk pharmacotherapy.
The patient is being started on a TNF-alpha inhibitor (infliximab) and a disease-modifying antirheumatic drug (methotrexate).
Different immunosuppressive medications have unique adverse effect profiles and require specific baseline screening protocols.
2
Determine the infectious disease screening requirements for TNF-alpha inhibitors.
TNF-alpha inhibitors require baseline screening for latent tuberculosis and hepatitis B due to the high risk of fatal reactivation.
TNF-alpha is crucial for granuloma maintenance (preventing tuberculosis dissemination) and viral clearance.
3
Evaluate the need for other proposed screening tests based on patient factors and drug mechanisms.
Routine echocardiography, TPMT testing, and ANA/anti-dsDNA screening are not indicated for this specific drug combination in an asymptomatic patient.
Screening must be evidence-based and directly tailored to the specific risks of the prescribed medications, avoiding unnecessary testing based on unrelated contraindications.

Anahtar Kavram

Prior to initiating TNF-alpha inhibitors (e.g., infliximab) and methotrexate, patients must undergo baseline screening for latent tuberculosis (via IGRA or tuberculin skin test) and hepatitis B (via surface antigen and core antibody testing) to prevent severe disease reactivation.
Bu soruyu puanla